Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maaike van Putten

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Journal of Molecular and Cellular Cardiology|February 4, 2014
Low dystrophin levels in heart can delay heart failure in mdx miceMaaike van Putten, Elizabeth M van der Pijl, Margriet Hulsker, et al.
Nucleic Acid Therapeutics|November 27, 2023
Challenges of Assessing Exon 53 Skipping of the Human <i>DMD</i> Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular DystrophySarah Engelbeen, Daniel O'Reilly, Davy Van De Vijver, et al.
Nucleic Acid Therapeutics|October 21, 2022
Efficient Downregulation of <i>Alk4</i> in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular DystrophySarah Engelbeen, Svetlana Pasteuning-Vuhman, Joke Boertje-van der Meulen, et al.
Scientific Reports|May 8, 2021
Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse modelGerard A Marchal, Maaike van Putten, Arie O Verkerk, et al.
Molecular Therapy. Nucleic Acids|November 19, 2014
Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophyMaaike van Putten, Courtney Young, Sjoerd van den Berg, et al.
Genes, Brain, and Behavior|June 5, 2024
Learning, memory and blood-brain barrier pathology in Duchenne muscular dystrophy mice lacking Dp427, or Dp427 and Dp140Minou Verhaeg, Kevin Adamzek, Davy van de Vijver, et al.
Plos One|August 21, 2019
Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2FIngrid E C Verhaart, Kayleigh Putker, Davy van de Vijver, et al.
Disease Models & Mechanisms|January 31, 2025
The behavioural consequences of dystrophinopathyMinou A T Verhaeg, Elizabeth M van der Pijl, Davy van de Vijver, et al.
Journal of Neuromuscular Diseases|February 27, 2018
Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The NetherlandsMaaike van Putten, Annemieke Aartsma-Rus, Miranda D Grounds, et al.
Molecular Therapy. Nucleic Acids|December 2, 2015
Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular DystrophySilvana M G Jirka, Christa L Tanganyika-de Winter, Joke W Boertje-van der Meulen, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal of Molecular and Cellular Cardiology|February 4, 2014
Low dystrophin levels in heart can delay heart failure in mdx miceMaaike van Putten, Elizabeth M van der Pijl, Margriet Hulsker, et al.
Nucleic Acid Therapeutics|November 27, 2023
Challenges of Assessing Exon 53 Skipping of the Human <i>DMD</i> Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular DystrophySarah Engelbeen, Daniel O'Reilly, Davy Van De Vijver, et al.
Nucleic Acid Therapeutics|October 21, 2022
Efficient Downregulation of <i>Alk4</i> in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular DystrophySarah Engelbeen, Svetlana Pasteuning-Vuhman, Joke Boertje-van der Meulen, et al.
Scientific Reports|May 8, 2021
Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse modelGerard A Marchal, Maaike van Putten, Arie O Verkerk, et al.
Molecular Therapy. Nucleic Acids|November 19, 2014
Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophyMaaike van Putten, Courtney Young, Sjoerd van den Berg, et al.
Genes, Brain, and Behavior|June 5, 2024
Learning, memory and blood-brain barrier pathology in Duchenne muscular dystrophy mice lacking Dp427, or Dp427 and Dp140Minou Verhaeg, Kevin Adamzek, Davy van de Vijver, et al.
Plos One|August 21, 2019
Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2FIngrid E C Verhaart, Kayleigh Putker, Davy van de Vijver, et al.
Disease Models & Mechanisms|January 31, 2025
The behavioural consequences of dystrophinopathyMinou A T Verhaeg, Elizabeth M van der Pijl, Davy van de Vijver, et al.
Journal of Neuromuscular Diseases|February 27, 2018
Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The NetherlandsMaaike van Putten, Annemieke Aartsma-Rus, Miranda D Grounds, et al.
Molecular Therapy. Nucleic Acids|December 2, 2015
Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular DystrophySilvana M G Jirka, Christa L Tanganyika-de Winter, Joke W Boertje-van der Meulen, et al.
Pageof 7